Progenics Pharmaceuticals, Inc.

New York,  NY 
United States
  • Booth: 3630

Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics'' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis tools. Progenics'' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.